Investment, Funding & Disinvestments

Health Minister Khaled Abdel Ghaffar discussed the proposed fund and potential areas of cooperation with representatives of Gold Rock Venture during a meeting at the ministry’s headquarters in New Alamein.

The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.

AsymBio plans to use the additional capital to expand its research and development capabilities, GMP manufacturing lines and high-containment facilities.

The newly raised capital will enable Inocras to expand its commercial operations and clinical infrastructure across the United States.

Under the definitive agreement, KKR will acquire all outstanding shares of Integer Holdings for US$127 per share in cash.

More than 600 delegates are expected to attend the Region’s main annual forum for health governance and policymaking.

The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.

The partnership will support Nigeria’s post-marketing vaccine surveillance system by evaluating innovative screening devices and expanding routine laboratory testing for vaccine lots.

Its educational programs cover pediatric dentistry, airway health, sleep-disordered breathing, oral function, early facial growth, interceptive orthodontics and myofunctional therapy.